TY  - JOUR
AU  - Socinski, Mark A
AU  - Kaye, Frederic J
AU  - Spigel, David R
AU  - Kudrik, Fred J
AU  - Ponce, Santiago
AU  - Ellis, Peter M
AU  - Majem, Margarita
AU  - Lorigan, Paul
AU  - Gandhi, Leena
AU  - Gutierrez, Martin E
AU  - Nepert, Dale
AU  - Corral, Jesus
AU  - Paz Ares, Luis Gonzaga
PY  - 2017
DO  - 10.1016/j.cllc.2016.09.002
SN  - 15257304
UR  - http://hdl.handle.net/20.500.12105/7424
AB  - INTRODUCTION: This trial assessed the safety and efficacy of LM in combination with carboplatin/etoposide therapy compared to carboplatin/etoposide treatment alone in patients with previously untreated extensive-disease small-cell lung cancer...
LA  - eng
PB  - CIG MEDIA GROUP
KW  - Clinical trial
KW  - Combination therapy
KW  - SCLC
KW  - Targeted drug delivery
KW  - Tolerability
KW  - Adult
KW  - Aged
TI  - Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease
TY  - journal article
ER  -